Search

Your search keyword '"Rupp, J."' showing total 7 results
Start Over Author "Rupp, J." Journal european respiratory journal
7 results on '"Rupp, J."'

5. A longitudinal analysis of pneumococcal vaccine serotypes in pneumonia patients in Germany.

Author

Bahrs C, Kesselmeier M, Kolditz M, Ewig S, Rohde G, Barten-Neiner G, Rupp J, Witzenrath M, Welte T, and Pletz MW

Subjects
Germany, Heptavalent Pneumococcal Conjugate Vaccine, Humans, Pneumococcal Vaccines, Serogroup, Serotyping, Vaccines, Conjugate, Pneumococcal Infections prevention & control, Pneumonia, Pneumococcal prevention & control
Abstract

Competing Interests: Conflict of interest: C. Bahrs is a member of the scientific advisory board of GSK, reports personal fees from Pfizer for lectures, and has received support for attending meetings and travel, all outside the submitted work. Conflict of interest: M. Kesselmeier declares no conflict of interest. Conflict of interests: M. Kolditz reports personal fees from Berlin Chemie, Boehringer, AstraZeneca, Biotest, Novartis, GSK, Gilead, Pfizer and MSD, and a research grant from Pfizer, outside the submitted work. Conflict of interest: S. Ewig is member of the scientific advisory board of Pfizer. Conflict of interest: G. Rohde reports personal fees from AstraZeneca, Berlin Chemie, BMS, Pfizer, Boehringer Ingelheim, Solvay, Insmed, GSK, Essex Pharma, MSD, Grifols, Chiesi, Vertex, Roche, Takeda and Novartis for lectures including service on speakers’ bureaus and/or consultancy during advisory board meetings, and personal fees from GSK for travel accommodations/meeting expenses, outside the submitted work. Conflict of interest: As part of her activity as a member of the executive bodies, G. Barten-Neiner reports economic connections to the following diagnostic and pharmaceutical companies: ThermoFisher Scientific/BRAHMS, Alere Technologies GmbH, Merck Sharp & Dohme Corp., Pfizer Pharma GmbH, R-Biopharm AG and Helmut Hund GmbH. Conflict of interest: J. Rupp has nothing to disclose. Conflict of interest: M. Witzenrath received personal fees from AstraZeneca, Bayer Health Care, Berlin Chemie, Biotest, Chiesi, Novartis and Teva, and research funding from Actelion, Bayer Health Care, Biotest and Boehringer Ingelheim, all unrelated to the current work. Conflict of interest: T. Welte is the head of clinical studies and a member of the speakers’ bureau for Pfizer, Bio Merieux and Roche Diagnostics, and is a consultant to Pfizer and MSD. Conflict of interest: M.W. Pletz is a consultant to and a member of the speakers’ bureau for Bayer, MSD, Pfizer, meduptodate, Thermofisher and Novartis, and has received research grants from Pfizer.

Published
2022
Full Text
View/download PDF

6. Complications of nasal and pharyngeal swabs: a relevant challenge of the COVID-19 pandemic?

Author

Föh B, Borsche M, Balck A, Taube S, Rupp J, Klein C, and Katalinic A

Subjects
Humans, COVID-19, Nasopharynx virology, Pandemics, Specimen Handling adverse effects
Abstract

Competing Interests: Conflict of interest: B. Föh has nothing to disclose. Conflict of interest: M. Borsche has nothing to disclose. Conflict of interest: A. Balck has nothing to disclose. Conflict of interest: S. Taube has nothing to disclose. Conflict of interest: J. Rupp has nothing to disclose. Conflict of interest: C. Klein reports personal fees from Centogene GmbH, outside the submitted work. Conflict of interest: A. Katalinic reports grants from State of Schleswig-Holstein, Germany and the Federal Ministry of Education and Research, Germany, during the conduct of the study.

Published
2021
Full Text
View/download PDF

7. Macrolide combination therapy for patients hospitalised with community-acquired pneumonia? An individualised approach supported by machine learning.

Author

König R, Cao X, Oswald M, Forstner C, Rohde G, Rupp J, Witzenrath M, Welte T, Kolditz M, and Pletz M

Subjects
Adult, Aged, Aged, 80 and over, Community-Acquired Infections drug therapy, Community-Acquired Infections mortality, Drug Therapy, Combination, Europe, Female, Hospitalization, Humans, Male, Middle Aged, Pneumonia, Bacterial mortality, Propensity Score, Prospective Studies, Severity of Illness Index, Treatment Outcome, Anti-Bacterial Agents therapeutic use, Machine Learning, Macrolides therapeutic use, Pneumonia, Bacterial drug therapy, beta-Lactams therapeutic use
Abstract

Background: The role of macrolide/β-lactam combination therapy in community-acquired pneumonia (CAP) of moderate severity is a matter of debate. Macrolides expand the coverage to atypical pathogens and attenuate pulmonary inflammation, but have been associated with cardiovascular toxicity and drug interactions. We developed a decision tree based on aetiological and clinical parameters, which are available ex ante to support a personalised decision for or against macrolides for the best clinical outcome of the individual patient., Methods: We employed machine learning in a cross-validation scheme based on a well-balanced selection of 4898 patients after propensity score matching to data available on admission of 6440 hospitalised patients with moderate severity (non-intensive care unit patients) from the observational, prospective, multinational CAPNETZ study. We aimed to improve the primary outcome of 180-day survival., Results: We found a simple decision tree of patient characteristics comprising chronic cardiovascular and chronic respiratory comorbidities as well as leukocyte counts in the respiratory secretion at enrolment. Specifically, we found that patients without cardiovascular or patients with respiratory comorbidities and high leukocyte counts in the respiratory secretion benefit from macrolide treatment. Patients identified to be treated in compliance with our treatment suggestion had a lower mortality of 27% (OR 1.83, 95% CI 1.48-2.27; p<0.001) compared to the observed standard of care., Conclusion: Stratifying macrolide treatment in patients following a simple treatment rule may lead to considerably reduced mortality in CAP. A future randomised controlled trial confirming our result is necessary before implementing this rule into the clinical routine., Competing Interests: Conflict of interest: None declared., (Copyright ©ERS 2019.)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results